Appleby’s Hong Kong office acts as Cayman Islands and BVI counsel for Shenzhen YHLO Biotech Co., Ltd. on its listing on the STAR Market of the Shanghai Stock Exchange
Appleby’s Hong Kong office acted as Cayman Islands and BVI counsel to Shenzhen YHLO Biotech Co., Ltd. (stock code: 688575) (YHLO Biotech) in relation to its listing on the STAR Market of the Shanghai Stock Exchange on 17 May 2021, with proceeds of approximately RMB 606.8 million.
The Hong Kong team was led by Counsel Vincent Chan.
YHLO Biotech is a leading company of immunoassay solutions in China, specialised in developing, manufacturing and distributing in-vitro diagnostic instruments and reagents for diagnosis of autoimmune diseases, reproductive health, infectious diseases and others. It was founded in 2008 and is headquartered in Shenzhen China.
Vincent commented “As a leading specialist in Hong Kong for offshore initial public offerings work, this deal further demonstrates our expertise and capability in helping clients with their listings in Asia.”
Our Hong Kong Capital Markets team is highly regarded for their extensive expertise in supporting offshore companies with IPOs, introductions, placements and listings of both equity and debt securities on the Hong Kong, US, Singapore and many other internationally recognised stock exchanges.
